A Phase 2, Two-Stage, Serial Cohort Dose Escalation and Expansion Study of a Single Intravenous Infusion of HBI 3000 for the Conversion of Atrial Fibrillation (AF) of Recent Onset
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Sulcardine (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; Therapeutic Use
- Acronyms HBI-3000-402
- Sponsors HUYA Bioscience International
- 07 Jan 2025 Planned End Date changed from 1 Dec 2024 to 30 Jun 2025.
- 07 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 30 Jun 2025.
- 18 Nov 2024 Results presented at the American Heart Association Scientific Sessions 2024.